Search results for "Drug"

showing 10 items of 20161 documents

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

2018

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%). …

0301 basic medicineAdultmedicine.medical_specialtyAntimetabolites AntineoplasticMyeloidAdolescentDatabases FactualAzacitidineDecitabineSalvage therapyDecitabineCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRefractoryInternal medicinehemic and lymphatic diseasesmedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overSalvage TherapyMyeloid Neoplasiabusiness.industryRemission InductionRetrospective cohort studyHematologyDNA MethylationMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaLeukemia Myeloid Acute030104 developmental biologymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAdolescent; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Cohort Studies; DNA Methylation; Databases Factual; Decitabine; Humans; Leukemia Myeloid Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adultbusinessmedicine.drug
researchProduct

Head, Neck, and Abdominopelvic Septic Thrombophlebitis: Current Evidence and Challenges in Diagnosis and Treatment.

2020

AbstractSeptic thrombophlebitis (STP) is a complex, cross-disciplinary clinical condition that combines a localized infection with a neighboring venous thrombosis. STP can occur at several possible anatomic sites, such as dural sinuses, jugular vein (Lemierre syndrome), portal vein (pylephlebitis), and pelvic veins. Its high mortality in the preantibiotic era improved considerably with the introduction of modern antibiotics. However, little evidence exists to date to guide its clinical management. The incidence of STP or its risk factors may be increasing, and its mortality may still be considerable. These trends would have far-reaching implications, especially in the setting of increasing …

0301 basic medicineAdultmedicine.medical_specialtyPylephlebitismedicine.drug_class030204 cardiovascular system & hematologyThrombophlebitisPelvis03 medical and health sciences0302 clinical medicineRisk FactorsJugular veinSepsisAbdomenMedicineHumansSeptic thrombophlebitisIntensive care medicineVenous Thrombosisbusiness.industryPortal VeinIncidence (epidemiology)IncidenceAnticoagulantAnticoagulantsHematologyBacterial InfectionsLemierre SyndromeThrombophlebitismedicine.diseaseAnti-Bacterial AgentsVenous thrombosis030104 developmental biologyObservational studyDrug Therapy CombinationFemaleJugular VeinsbusinessHeadNeckHamostaseologie
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct

Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.

2015

Peer reviewed

0301 basic medicineAdultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmenteducationPain5-AMINOLEVULINIC ACIDHuman skinPhotodynamic therapyPilot ProjectsEUROPEAN GUIDELINESDermatology030105 genetics & heredityAdministration Cutaneousphotodynamic therapy (PDT)ihosyöpä03 medical and health sciencesDouble-Blind MethodMedicineHumansPhotosensitizerProdrugsSkinACTINIC KERATOSESihoPhotosensitizing Agentsbusiness.industryGeneral MedicineActinic keratosesAminolevulinic AcidDermatologyHealthy Volunteers3. Good healthOikeuslääketiede ja muut lääketieteet - Forensic science and other medical sciencesREDUCES INFLAMMATIONPhotochemotherapyErythema3121 General medicine internal medicine and other clinical medicinebusinessActa dermato-venereologica
researchProduct

Observational prospective study on Lactobacillus plantarum P 17630 in the prevention of vaginal infections, during and after systemic antibiotic ther…

2018

We performed a prospective cohort parallel observational study on the use of Lactobacillus plantarum P 17630 in the prevention of vaginal infections. Eligible were women with a diagnosis of bacterial vaginosis (15 days) and documented history of recurrent vaginal infections; and/or cystitis (15 days); and/or treatment with antibiotics for bacterial respiratory tract infections during the week before the study entry. Study subjects were prescribed Lactobacillus plantarum P 17630  100.000.000 UFC one vaginal capsule per day for 6 days, then a capsule per week for 16 weeks. Eligible subjects were enrolled in two parallel cohorts: 85 women using (group A) and 39 not using (group B) Lactobacillu…

0301 basic medicineAdultmedicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsPopulationGroup B03 medical and health sciences0302 clinical medicineInternal medicineCystitismedicineSecondary PreventionHumansProspective StudiesProspective cohort studyeducationVaginitisRespiratory Tract Infectionseducation.field_of_studybiologyGenitourinary systembusiness.industryProbioticsPreventionfood and beveragesObstetrics and GynecologyMiddle Agedmedicine.diseasebiology.organism_classification030205 complementary & alternative medicineAnti-Bacterial AgentsObservational studyFemaleBacterial vaginosisbusinessbacterial vaginosis; Lactobacillus plantarum; Prevention; Adult; Anti-Bacterial Agents; Cystitis; Female; Humans; Middle Aged; Probiotics; Prospective Studies; Respiratory Tract Infections; Secondary Prevention; Vaginitis; Lactobacillus plantarum; Obstetrics and GynecologyLactobacillus plantarumbacterial vaginosis; Lactobacillus plantarum; Preventionbacterial vaginosisLactobacillus plantarum
researchProduct

Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions.

2020

Type 2 diabetes (T2D) is a very prevalent, multisystemic, chronic metabolic disorder closely related to atherosclerosis and cardiovascular diseases. It is characterised by mitochondrial dysfunction and the presence of oxidative stress. Metformin is one of the safest and most effective anti-hyperglycaemic agents currently employed as first-line oral therapy for T2D. It has demonstrated additional beneficial effects, unrelated to its hypoglycaemic action, on weight loss and several diseases, such as cancer, cardiovascular disorders and metabolic diseases, including thyroid diseases. Despite the vast clinical experience gained over several decades of use, the mechanism of action of metformin i…

0301 basic medicineAdvanced glycation end product (AGE)AMP-activated protein kinase (AMPK)endocrine system diseasesglycerol 3-phosphate dehydrogenase (GPD)Clinical Biochemistrytype 1 diabetes (T1D)Type 2 diabetesmTORC1Review Articleelectron transport chain (ETC)PharmacologyMitochondrionmedicine.disease_causeBiochemistry0302 clinical medicineLeukocytesCREB-binding protein (CBP)inner mitochondrial membrane (IMM)lcsh:QH301-705.5lcsh:R5-920cAMP response element-binding (CREB)glucagon-like peptide 1 (GLP-1)type 2 diabetes (T2D)Type 2 diabetesMetforminMetforminMitochondriamedicine.anatomical_structurereactive nitrogen species (RNS)reactive oxygen species (ROS)sirtuin (SIRT)medicine.symptomlcsh:Medicine (General)cardiovascular diseases (CVD)medicine.drugEndotheliumnitric oxide synthase (NOS)polycystic ovary syndrome (PCOS)Pathophysiologyinsulin resistance (IR)superoxide dismutase (SOD)03 medical and health sciencesglycated haemoglobin (HbA1c)medicineorganic cation transporter (OCT)HumansEndotheliumintercellular adhesion molecule-1 (ICAM-1)business.industryoxidative phosphorylation (OXPHOS)Organic Chemistryperoxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)AMPKmedicine.diseaseAtherosclerosisvascular cell adhesion molecule-1 (VCAM-1)Treatment030104 developmental biologylcsh:Biology (General)Mechanism of actionDiabetes Mellitus Type 2Oxidative stressbusinessinsulin receptor substrate (IRS)030217 neurology & neurosurgeryOxidative stress
researchProduct

New approach to generating insights for aging research based on literature mining and knowledge integration.

2017

The proportion of the elderly population in most countries worldwide is increasing dramatically. Therefore, social interest in the fields of health, longevity, and anti-aging has been increasing as well. However, the basic research results obtained from a reductionist approach in biology and a bioinformatic approach in genome science have limited usefulness for generating insights on future health, longevity, and anti-aging-related research on a case by case basis. We propose a new approach that uses our literature mining technique and bioinformatics, which lead to a better perspective on research trends by providing an expanded knowledge base to work from. We demonstrate that our approach …

0301 basic medicineAgingAging and Cancerlcsh:MedicineOtologyDeafnessBioinformaticsBiochemistryField (computer science)Database and Informatics MethodsOxidative DamageKnowledge integrationBasic researchDrug DiscoveryMedicine and Health SciencesData MiningPost-Translational Modificationlcsh:ScienceHearing DisordersEnergy-Producing OrganellesGlycationReductionismMultidisciplinaryCancer Risk FactorsMitochondriaKnowledgeOncologyKnowledge baseSocial interestCellular Structures and OrganellesInformation TechnologyResearch ArticleComputer and Information SciencesDrug Research and DevelopmentBioinformaticsBioenergeticsBiologyResearch and Analysis Methods03 medical and health sciencesLead (geology)Research basedHumansPharmacologybusiness.industrylcsh:RBiology and Life SciencesProteinsCell BiologyData science030104 developmental biologyOtorhinolaryngologylcsh:QReactive Oxygen SpeciesbusinessPLoS ONE
researchProduct

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms

2017

Life expectancy and the number of elderly people are progressively increasing around the world. Together with other pathologies, allergic diseases also show an increasing incidence in geriatric age. This is partly due to the growing emphasis on a more accurate and careful diagnosis of the molecular mechanisms that do not allow to ignore the real pathogenesis of many symptoms until now unknown, and partly to the fact that the allergic people from 20 years ago represent the elderly population now. Moreover, environmental pollution predisposes to the onset of allergic asthma and dermatitis which are the result of internal pathologies more than the expression of allergic manifestations. At the …

0301 basic medicineAgingAllergyAllergyUrticariamedicine.medical_treatmentImmunologyEnvironmental pollutionReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesElderlyImmune systemAnaphylaxiFood allergyFood allergymedicineImmunology and AllergyAnaphylaxisMolecular BiologyAsthmabusiness.industryConjunctivitiImmunotherapyConjunctivitismedicine.diseaseAsthmaDrug reaction030104 developmental biologyageAging; Allergy; Anaphylaxis; Asthma; Conjunctivitis; Drug reaction; Elderly; Food allergy; Immunotherapy; Urticaria; Immunology and Allergy; Immunology; Molecular BiologyImmunologyLife expectancyImmunotherapybusinessAnaphylaxisClinical and Molecular Allergy
researchProduct

Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtu…

2020

A number of aging-related disorders (ARD) have been related to oxidative stress (OS) and mitochondrial dysfunction (MDF) in a well-established body of literature. Most studies focused on cardiovascular disorders (CVD), type 2 diabetes (T2D), and neurodegenerative disorders. Counteracting OS and MDF has been envisaged to improve the clinical management of ARD, and major roles have been assigned to three mitochondrial cofactors, also termed mitochondrial nutrients (MNs), i.e., alpha-lipoic acid (ALA), Coenzyme Q10 (CoQ10), and carnitine (CARN). These cofactors exert essential-and distinct-roles in mitochondrial machineries, along with strong antioxidant properties. Clinical trials have mostly…

0301 basic medicineAgingAntioxidantUbiquinonemedicine.medical_treatmentmitochondrial nutrientsReviewoptic neuropathiesType 2 diabetesPharmacologyMitochondrionmedicine.disease_causeAntioxidantslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineCardiovascular Diseaseoxidative stressaging-related disorderslcsh:QH301-705.5SpectroscopyThioctic AcidMitochondrial nutrientNeurodegenerative DiseasesGeneral MedicineComputer Science ApplicationsMitochondriaCardiovascular DiseasesAntioxidantmedicine.drugHumanCatalysisAging-related disorderCell LineInorganic Chemistry03 medical and health sciencesCarnitinemedicineAnimalsHumansMicrobiomeCarnitinePhysical and Theoretical ChemistryMolecular BiologyCoenzyme Q10business.industryAnimalOrganic ChemistryOxidative Stremedicine.diseaseClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryDiabetes Mellitus Type 2MicrobiomeOptic neuropathiebusinessMitochondrial dysfunction030217 neurology & neurosurgeryOxidative stress
researchProduct